triple negative breast cancer > 통합검색

통합검색

한빛사

내가 찾은 검색어

1triple negative breast cancer

'triple negative breast cancer' 에 대한 통합검색결과 131건입니다.

한빛사131건

최신순
관련도순

- 김우태(순천향대학교)
PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge
- Exp. Mol. Med. Apr 10 2026, | https://doi.org/10.1038/s12276-026-01673-8
- 2026.04
- 생명과학
A localization gate licenses chaperone-mediated autophagy of SNAI (snail) to restrain epithelial-mesenchymal transition competence in breast cancer
- Autophagy Mar 23 2026, | https://doi.org/10.1080/15548627.2026.2646240
- 2026.03
- 생명과학
- Ben Ho Park(Vanderbilt University Medical Center)
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Mini
- J. Clin. Oncol. Mar 10 2026, | https://doi.org/10.1200/JCO-25-02934
- 2026.03
Cuproptosis-Inducing Photothermal Nanotherapy Coupled with ECM Destabilization Drives Potent Tumor Regression and Immune Reawakening.
- Mater. Today Bio Available online 2 March 2026, 103003 | https://doi.org/10.1016/j.mtbio.2026.103003
- 2026.03
- 바이오·의료융합
Low-dose radiation generated ROS-activatable doxorubicin prodrug loaded liposome nanoparticles for triple-negative breast cancer treatment
- J. Control. Release Feb 27 2026, S0168-3659(26)00152-5 | https://doi.org/10.1016/j.jconrel.2026.114750
- 2026.02
- 바이오·의료융합
Redox-driven mechanoregulation of invasive TNBC cells using poly (tannic acid) nanospheres
- Nano Today Volume 66, February 2026, 102907 | https://doi.org/10.1016/j.nantod.2025.102907
- 2026.02
- 바이오·의료융합
Electrochemical platform for in situ metabolic profiling and therapeutic evaluation of triple-negative breast cancer
- Chem. Eng. J. Available online 20 January 2026 | https://doi.org/10.1016/j.cej.2026.173253
- 2026.01
- 바이오·의료융합
Ligand-directed oral lipidic nanoplatform enables sustained ferroptosis and immune reprogramming via multivalent transporter-mediated metronomic deliv
- Theranostics Published 2026-1-1; 16(6):2952-2983. doi:10.7150/thno.124189
- 2026.01
- 의약학
고동미

고려대학교 의과대학

삼중음성유방암(Triple-negative breast cancer, TNBC)은 전체 유방암 중 약 15~20%를 차지하며, 에스트로겐 수용체(ER), 프로게스테론 수용체(PR), 그리고 HER2 수용체가 모두 음성인 난치성 유방암입니다. 명확한 표적 분자가 존재하지 않기 때문에, 기존의 호르몬 치료나 HER2 표적치료제가 적용되지 않아 주로 세포독성 항암제에 의존하고 있으며, 치료 후에도 재발과 전이가 잦아 예후가 매우 불량합니다. 특히 치료 후에도 살아남는 암줄기세포(Cancer stem-like cells, CSCs)가 약물 내성과 종양 재발의 주요 원인으로 지목되면서, 이를 표적할 수 있는 새로운 치료 전략이 필요합니다.
- Exp. Hematol. Oncol.
- 2026.01.28
- 정원우(Wake Forest Institute for Regenerative Medicine)
- 이상진(Wake Forest School of Medicine)
The effect of stiffness on cell behavior and drug resistance in patient-derived breast cancer organoids
- Acta Biomater. Dec 13 2025, S1742-7061(25)00933-X | https://doi.org/10.1016/j.actbio.2025.12.026
- 2025.12
- 바이오·의료융합
Noncanonical association of EZH2 with E2F1 promotes tumor proliferation through chromatin remodeling
- Exp. Mol. Med. 19 December 2025 | https://doi.org/10.1038/s12276-025-01603-0
- 2025.12
- 생명과학
- 강래형(University of Wisconsin-Madison, 단국대학교)
Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer
- ACS Nano Nov 19 2025, | https://doi.org/10.1021/acsnano.5c13083
- 2025.11
- 의약학
Single-cell transcriptomics of the myeloid milieu reveals an angiogenic niche in triple-negative breast cancer
- Exp. Mol. Med. Nov 07 2025, | https://doi.org/10.1038/s12276-025-01571-5
- 2025.11
- 생명과학
- 이상남(성균관대학교 나노과학기술원 (SAINT))
- 임용택(성균관대학교)
Focused ultrasound-triggered doxorubicin liposomes reshape tumor microenvironment to boost checkpoint depletion in triple-negative breast cancer model
- J. Control. Release Available online 4 November 2025, 114389 | https://doi.org/10.1016/j.jconrel.2025.114389
- 2025.11
- 바이오·의료융합
Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer
- Exp. Hematol. Oncol. Oct 22 2025, 14 (1) | https://doi.org/10.1186/s40164-025-00716-6
- 2025.10
- 의약학
Synergistic Effects of Radiotherapy and PD?1 Blockade in a Human?Mimetic BRCAness Model of Triple-Negative Breast Cancer
- Int. J. Biol. Sci. 2025-10-1; 21(14):6270-6284 | https://doi.org/10.7150/ijbs.118427
- 2025.10
- 생명과학
- 홍태훈(Tokyo Medical University)
  Interview
Glycoliposomes target lymphatic dendritic cells in a size-dependent manner to activate natural killer T cells against breast tumors
- J. Control. Release Sep 26 2025, S0168-3659(25)00887-9 | https://doi.org/10.1016/j.jconrel.2025.114274
- 2025.09
- 바이오·의료융합
Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy
- Signal Transduct. Target. Ther. 26 September 2025;10:310 (2025) | https://doi.org/10.1038/s41392-025-02405-6
- 2025.09
- 바이오·의료융합
Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer
- Clin. Cancer Res. Aug 20 2025, | https://doi.org/10.1158/1078-0432.CCR-24-3283
- 2025.08
- 의약학
- 함태훈(The Johns Hopkins University School of Medicine)
Quantitative MALDI imaging of aspirin metabolites in mouse models of triple-negative breast cancer
- Theranostics Published 2025-8-22;15. 18. 2025; doi:10.7150/thno.116819
- 2025.08
- 바이오·의료융합